emeis: Sales and business to end-March 2025 1
emeis (Paris:EMEIS):
Occupancy rate: further improvement in the first quarter, +2 points on average
Continued improvement in the Group's average occupancy rate, up +2pts to 87.0% (vs. 85.0% in Q1 2024 and 83.0% in Q1 2023), and reaching 88.0% on the mature scope (excluding recently opened facilities).
Occupancy rate for nursing homes up +2.1pts to 86.4% (vs. 84.3% in Q1 2024 and 81.8% in Q1 2023)
Strong increases in Northern Europe (+3pts to 85.3%), Central Europe (+2.6pts to 91.6%) and in France (+1.7pt to 86.4%)
First-quarter organic sales growth of +6.2%, driven by nursing homes and international markets
Organic sales growth of +6.2%, reflecting the gradual turnaround in the Group's activities following the measures taken over the past 24 months, driven in all zones by a favorable price effect (+3.7%) and an increase in occupancy rate (+1.8%), despite a slight decline in clinics (-0.4%).
Strong organic sales growth in the nursing home business (+9.6% year-on-year) ...
... and internationally (+11.4% in Northern Europe, +9.5% in Central Europe and +10.3% in Southern Europe and Latam)
Progress on the divestment program: over €1 billion of divestments secured by the end of April
At the end of March, over €1 billion of disposals had been secured since mid-2022, of which €760 million had already been cashed in.
More than €100m of new disposals secured since the beginning of the year
As a reminder, the Group aims to finalize €1.5 billion in disposals of operating and real estate assets between mid-2022 and the end of 2025, in order to further reduce its debt.
Discussions underway for a total of over €2 billion in potential real estate and operating asset disposals
2025 guidance confirmed: the recovery momentum since H2 2024 points in the right direction for 2025
The recovery momentum that began in the second half of 2024 should continue into 2025, allowing emeis to anticipate a further operational turnaround.
On a like-for-like basis 3, the Group anticipates a significant increase in EBITDAR of between +15% and +18% in 2025.
About emeis
With nearly 83,500 experts and professionals in the fields of health, care and support for the frail, emeis is present in some twenty countries and covers five business lines: psychiatric clinics, medical care and rehabilitation clinics, nursing homes, homecare services and residences.
Every year, emeis welcomes nearly 280,000 residents, patients and beneficiaries. emeis is committed to meeting one of the major challenges facing our society: the growing number of people made vulnerable by accidents, old age and mental illness.
emeis, 50.3% owned by Caisse des Dépôts, CNP Assurances, MAIF and MACSF Epargne Retraite, is listed on Euronext Paris (ISIN: FR001400NLM4) and is a member of the SBF 120 and CAC Mid 60 indices.
Site : www.emeis.com
1- Sales: significant growth driven by nursing homes and international scope
At the end of March 2025, Group sales stood at €1,445 million, up +5.2% (+€71 million) and +6.2% on an organic basis 4. This increase reflects the combination of three factors, all of which had a positive impact:
Positive price effect, supporting organic growth by +3.7%.
Increase in the average occupancy rate to end-March of around +2pts, contributing +1.8% to organic growth.
Contribution of recently opened sites in 2024 and 2025 (contributing +0.8% to organic growth)
Organic growth in Group sales was mainly driven by nursing homes (almost 2/3 of Group business), where sales rose by almost +10% organically compared with Q1 2024, driven by a significant upturn in the average occupancy rate (by +2.1pts vs. Q1 2024).
The Clinics business was stable overall (-0.4% organic), despite a +1.5pt rise in occupancy rate, mainly due (notably in France) to non-recurring base effects, as well as a lower number of full hospitalization days in care facilities, also reducing the volume of business generated on private rooms.
Performance was particularly strong in European markets outside France, where organic growth rates approached or exceeded +10%, benefiting from strong price effects in Germany, Belgium and Austria in particular, higher occupancy rates in the Netherlands, Austria and Spain in particular, and the ramp-up of recently opened facilities in the Netherlands and Spain.
In France, organic sales growth in nursing homes (+3.6%) mainly reflects a favorable price effect and a 1.6pt increase in occupancy rate. This rate would have risen by almost +30bps if a positive (non-recurring) adjustment effect in the first quarter of 2024 had been taken into account. Adjusted for this effect, the organic growth rate would be around +4.0% for retirement homes in France.
However, sales for clinics in France in the first quarter of 2025 fell organically by -2.7%, half impacted by a lower number of full hospitalization days in care facilities, which also reduced the volume of business generated by private rooms, and half by non-recurring income in the first quarter of 2024, the effect of which on growth is expected to be diluted over the course of the year.
2- Occupancy rate: positive momentum confirmed
The Group's average occupancy rate rose by almost +2pts year-on-year to 87.0% at the end of March (vs. 85.0% at the end of March 2023), thus extending the favorable recovery trend started in 2024.
As a reminder, the average occupancy rate for the Group's sites, was 85.8% at end-2024, and 83.3% at end-2023.
The recovery was driven in particular by nursing homes, where the occupancy rate stood at 86.4% at the end of March, up +2.1pts year-on-year. It is also up +1.5pt for clinics, now reaching 89.2%.
It should be noted that these occupancy rates would be higher on the mature perimeter alone, excluding recent openings and facilities undergoing restructuring, whose occupancy rates are not yet mature. Excluding these facilities, the Group's average occupancy rate would be 88%. This effect is particularly significant in Southern Europe, where the restatement of very recently opened facilities shows an occupancy rate on the mature perimeter that is +5.5pts higher at 91.9%, up +2.9pts on the first quarter of 2024.
The trends that gradually emerged in 2024 are continuing into 2025, across all emeis markets. Although the levels achieved fall short of the Group's ambitions, the upward momentum is encouraging.
In France (41% of Group sales), the average occupancy rate now stands at 87.6%, up +1.7pt compared to the first quarter of 2024. This increase reflects a sequential improvement, quarter after quarter, in facility occupancy.
For nursing homes in France, the occupancy rate stood at 83.5%, up +1.6pt year-on-year. It is worth noting that at the end of 2024, the average occupancy rate for nursing homes in France was +1.1pt higher than in 2023. Then in the first quarter of 2025, this indicator is now +1.6pt higher than in the first quarter of 2024, reflecting an acceleration in the recovery momentum of this aggregate at the start of the year, compared with the already favorable momentum of 2024.
In Northern Europe (30% of sales), the momentum already established in 2024 is continuing, with occupancy up +3pts year-on-year. In Germany and Belgium, the significant improvement reflects the quality measures put in place, as well as - as in the Netherlands - the ramp-up of recently opened establishments.
In Central Europe (17% of sales), there has been a marked improvement, with occupancy rates now close to pre-covid levels, approaching 92%.
In Southern Europe and Latam (8% of sales), the opening of new facilities in the second half of 2024 (notably in Spain and Portugal) is having a transitory impact on the average occupancy rate. On a mature basis (excluding recent openings whose ramp-up is gradual), the occupancy rate in this region now stands at 91.9%, up +2.9pts year-on-year.
3- Progress of disposals: €1.03bn completed or secured by the end of April 2025
The volume of disposals signed since mid-2022 now stands at €1.03 billion 6, mainly comprising sale & leaseback transactions, but also the first operational asset disposals. This volume, up by more than €100 million on the figure announced at the end of December 2024, takes into account the signature of additional real estate asset disposals in France, the Netherlands and Brazil in the first quarter.
These disposals break down as follows :
€171 million 7 of operating assets sold to healthcare operators in the Czech Republic and Chile. The sale of the Czech Republic portfolio was subject to approval by the Czech competition authorities, which was obtained at the end of March. The transaction was therefore finalized on Monday, March 31, 2025, and the proceeds were received on the same day.
€589 million of finalized real estate disposals, including €286 million in 2024 (47% sale & leaseback)
€270million real estate transactions signed and secured at the end of March 2025, but not yet cashed in, of which nearly €158 million should be cashed in before the end of 2025.
As a reminder, in order to continue reducing its debt and meet its commitments to banking partners, the Group had raised its disposal targets to €1.5 billion (between mid-2022 and end-2025), including the sale of real estate assets (PropCo) and operating assets (OpCo). This ambition has now been confirmed and reinforced.
This ambition leaves almost €600 million of disposals still to be completed by the end of 2025, which is mobilizing the Group's teams on investment markets that are still convalescent, but which seem to be gradually reopening.
To date, more than €2 billion of potential disposals (PropCo and OpCo) are currently under discussion or negotiation between emeis and several potential buyers, demonstrating both the dynamism of the emeis teams and the growing appetite of investors for healthcare assets. These ongoing discussions far exceed the remaining target to be achieved by the end of the year, and give the Group considerable room for manoeuvre in the execution of its program.
Discussions on the various potential disposals are proceeding according to the Group's planned timetable.
4- Outlook and guidance 2025 reiterated
The outlook for the Group's reference markets over the medium term is particularly buoyant for care and support activities for the most vulnerable.
The population of seniors aged over 75 is set to grow by more than 30% over the next 10 years, to represent 14% of the population. As a result, the structural shortage of supply in the nursing home markets will grow each year, reaching a deficit of around 550,000 beds by 2030 and 800,000 beds by 2035 in the 5 main emeis markets. To illustrate the scale of this future shortfall, the French market currently boasts a total of 650,000 beds.
The prevalence of psychological disorders and chronic illnesses is also continuing to grow significantly, again creating a risk of insufficient supply in the years ahead.
This major shortage situation gives emeis solid visibility for the years ahead, with supply corresponding to fast-growing demand.
In the short term, the trajectory of operational recovery has been confirmed, particularly since the second half of 2024. This trend will continue into 2025 under the combined effects of an upturn in occupancy rates, the capture of favorable price effects and better control of operating expenses.
Each year, emeis will communicate the anticipated trends for the current year. The promising trends expected for 2025 seem to have been confirmed after the first few months of the year.
As a result, in 2025, the Group expects EBITDAR to rise by between +15% and +18% on a like-for-like basis (excluding the effects of any operational disposals in 2025) compared with 2024, thereby extending and accentuating the performance improvement momentum initiated in recent quarters.
DISCLAIMER
This document contains forward-looking statements that involve risks and uncertainties concerning the Group's future growth and profitability, and which could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements contained in this document constitute expectations of future events and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the Company's Universal Registration Document 2024, which is available on the Company's website and that of the AMF (www.amf-france.org).
1 Unaudited figures
2 Including a 'constant number of days' adjustment related to the calendar difference between 2024 and 2025 (leap year 2024), for an impact of 0.9pts on Group organic growth.
3 Excluding changes in operating perimeter that may occur during the year
4 Including a 'constant number of days' adjustment for the calendar difference between 2024 and 2025 (leap year 2024), representing an impact of 0.9pts on organic growth at Group level.
5 incl. downward adjustment of capacity at French clinics
6 Amount expressed as net selling value before repayment of associated debts
7 Enterprise value for the Czech Republic and Equity value for the share deal in Chile
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Business Wire
a day ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
a day ago
- Business Wire
General American Investors Files Certified Shareholder Report for Period Ended June 30, 2025
NEW YORK--(BUSINESS WIRE)--General American Investors Company, Inc., a closed-end investment company listed on the New York Stock Exchange (GAM), filed with the U.S. Securities and Exchange Commission (SEC) its Certified Shareholder Report (Form N-CSR) for the six-month period ended June 30, 2025. The Form N-CSR contains the Company's June 30, 2025 Semi-Annual Report and is available at the SEC's website: and the Company's website: The Semi-Annual Report is expected to be mailed to stockholders shortly. The Semi-Annual Report indicates that as of or for the six months ended: * After a distribution of $4.07 per share from net long-term capital gains and a dividend of $0.43 per share paid in December 2024 and a distribution of $0.25 per share from long-term capital gains paid in March 2025. Expand The largest stock holdings in the Company's portfolio as of June 30, 2025, included: Microsoft, Republic Services, Berkshire Hathaway, TJX Companies, and Amazon.
